Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Favipiravir - FUJIFILM Toyama Chemical

Drug Profile

Favipiravir - FUJIFILM Toyama Chemical

Alternative Names: Avigan; T-705; T-705a

Latest Information Update: 05 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Toyama Chemical
  • Developer BioDefense Therapeutics; FUJIFILM Holdings Corporation; FujiFilm Pharmaceuticals USA; FUJIFILM Toyama Chemical; Institut national de la sante et de la recherche medicale; MediVector; Toyama Chemical
  • Class Amides; Antivirals; Pyrazines; Small molecules
  • Mechanism of Action RNA replicase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Influenza virus infections
  • Phase III Viral infections
  • Phase II Ebola virus infections

Most Recent Events

  • 26 Oct 2018 FUJIFILM Corporation, Zhejiang Hisun Pharmaceutical, the China-Japan Friendship Clinic and the National Engineering Research Center for the Emergency Drug signed memorandum on clinical development of favipiravir injection in China
  • 24 Jun 2018 Biomarkers information updated
  • 28 Feb 2018 No recent reports of development identified for research development in Ebola-virus-infections in USA (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top